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structures retained in uremia.
Background. Advanced glycation end-products (AGEs)
have been identified to be accumulated in blood and tissues of
patients with end-stage renal disease (ESRD). AGEs have been
shown to modulate immune competent cell activities and in this
way they may contribute to the progression of atherosclerosis.
All studies in this context have been performed, however, with
generated mix of glycation compounds, and not with structures
similar to those encountered in uremia. In the present study, the
immunologic effect of specific AGE compounds, known to be
retained in uremia, has been evaluated.
Methods. Four albumin preparations, modified chemically
at lysine or arginine residues, respectively, to contain N-e-
carboxymethyllysine (CML albumin), N-e-carboxyethyllysine
(CEL albumin), glyoxal-induced imidazolinones (Arg I
albumin) or methylglyoxal-induced imidazolinones (Arg II
albumin) were applied. Their effect on chemiluminescence pro-
duction, CD14 expression, and the DNA synthesis of calcitriol-
differentiated HL-60 (monocyte/macrophage phenotype) was
studied.
Results. The phorbol 12-myristate 13-acetate (PMA)-
stimulated chemiluminescence production of the calcitriol dif-
ferentiated HL-60 cells was enhanced in the presence of CEL al-
bumin (44.1 ± 18.5 vs. 64.7 ± 28.1 counts 103/30 min) (P < 0.05),
Arg I albumin (46.4 ± 18.8 vs. 66.1 ± 32.6 counts 103/30 min)
(P < 0.05) and CML albumin (41.9 ± 25.5 vs. 60.9 ± 5.5 counts
103/30 min) (P = 0.0625) pointing to an increase in free radical
production. The latter AGE compounds also significantly in-
creased the calcitriol-induced CD14 expression on HL-60 cells
(1675 ± 796 vs. 2075 ± 1044; 768 ± 143 vs. 890 ± 150; 647 ± 63 vs.
716 ± 69 mean fluorescence intensity) (P < 0.05, respectively)
pointing to an increase in expression of the lipopolysaccharide
(LPS) receptor. Finally, the DNA synthesis of the calcitriol-
differentiated HL-60 cells was enhanced in the presence of Arg
I albumin [34.5 ± 4.6 vs. 27.7 ± 9.7% 5-bromo-2′-deoxyuridine
(BrdU)-positive cells] (P < 0.05) resulting in an increased cell
proliferation.
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Conclusion. Genuine AGE compounds, as they are encoun-
tered in the uremic condition, activate leukocyte response, and
hence could play a role in uremia related atherogenesis.
Until now, the research of the biologic effects of ad-
vanced glycation end-products (AGEs) has only been
performed with mixtures of AGEs, obtained after a long
lasting in vitro preparation process, whereby glucose is
brought into contact with albumin at a temperature of
37◦C in an aspecific way, resulting in “AGE-modified”
proteins containing several peptide-bound amino acid
derivatives of unknown concentration [1–3]. To the best
of our knowledge, no such studies have been undertaken
until now with proteins containing genuine AGE com-
pounds, as they are encountered in the serum of uremic
patients. Hence it remains unclear which of the known re-
tained AGE products, and to what extent, exert biologic
effects.
AGE compounds are generated through chemical re-
arrangements and degradation reactions from stable
Amadori products and Schiff-base adducts which are the
result of a nonenzymatic reaction of glucose or reducing
sugars with free amino groups [4]. Next to the genera-
tion of AGE compounds in the process of aging [5] and
during the progression of diabetes mellitus [5, 6], AGEs
were also identified in the blood and tissues of patients
with end-stage renal disease (ESRD). Oxidative and car-
bonyl stress were pointed out as responsible actors in ure-
mia, rather than reactions with glucose [7]. It was recently
demonstrated that AGEs accumulate in atheromatous
plaques of the aortic wall of subjects with ESRD, where
they may further contribute to a more rapid progression
of atherosclerosis [8]. AGEs can also neutralize the pro-
cess that protects the vascular bed against aggregation
and proliferation of cells, two key elements in athero-
genesis. Most in vitro work has shown AGEs to be part
of complex interactions within the context of oxidative
stress and vascular damage, particulary in atherosclero-
sis [9] and in the accelerated vascular damage that occurs
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in diabetes, as well as in other conditions such as ESRD
[10, 11].
The purpose of our study, therefore, was to evalu-
ate changes due to the presence of individual, chemi-
cally characterized AGE compounds, which are known
to be retained in renal failure, and play a possible
role in immune dysfunction and atherogenesis. For
that purpose, the albumin-modified AGE compounds
N-e-carboxymethyllysine (CML albumin), N-e-carboxy-
ethyllysine (CEL albumin), arginine modified with
glyoxal (Arg I albumin) and arginine modified with
methylglyoxal (Arg II albumin) were chosen.
CML may result from the reaction of lysine side chains
with glyoxal [12] and the oxidative cleavage of fruc-
tosamines [13]. Plasma levels of CML in hemodialysis
patients by far exceed those in normal or diabetic sub-
jects, possibly due to increased carbonyl stress in uremia
[14]. Furthermore, CML represents an important ligand
for the AGE-receptor [15]. CEL, a structural anologue of
CML, is formed from the reaction of lysine and methyl-
glyoxal or in the course of lipid peroxidation during aging
[16]. As it is known that, in addition to lysine, also arginine
represents a major target for carbohydrate-induced pro-
tein modification, albumin samples derivatized on argi-
nine (included to distiguish from CML and CEL which
originate from modification of lysine) with methylgly-
oxal and glyoxal were submitted to evaluation as well.
During reaction of arginine with glucose degradation
products, imidazolinones are formed as predominant re-
action product [17–19]. Recent reports indicate that the
methylimidazolinone derived from methylglyoxal is ac-
cumulated as one of the AGEs in uremia [20].
The present study investigates the effect of these spe-
cific AGEs present in uremia on leukocyte function by
analyzing free radical production, CD14 expression and
DNA synthesis [5-bromo-2′-deoxyuridine (BrdU) incor-
poration] by calcitriol-differentiated HL-60 cells (mono-
cyte/macrophage phenotype).
METHODS
Preparation of AGEs
Carboxymethylated albumin (CML albumin). Gly-
oxylic acid (3.5 mmol per g albumin) was added to a
solution of bovine serum albumin (BSA) (Sigma Chem-
ical Co., St. Louis, MO, USA) (20 mg/mL) in phosphate
buffer (1/15 mol/L, pH 7.4), corresponding to a molar ra-
tio between glyoxylic acid and lysine of 4:1. The pH was
adjusted to 7.4 with 0.5 N NaOH, followed by addition
of 8.8 mmol NaBCNH3 per g albumin. After incubation
for 20 hours at 40◦C under constant stirring, the solution
was extensively dialyzed against distilled water and freeze
dried, resulting in a slightly yellow, crystalline powder.
Content of CML was measured by gas chromatography-
mass spectrometer (GC-MS) as described.
Carboxyethylated albumin (CEL albumin). Pyruvic
acid (13 mmol per g albumin) was added under nitro-
gen to a solution of BSA (20 mg/mL) in phosphate buffer
(1/15 mol/L, pH 7.4), corresponding to a molar ratio be-
tween pyruvic acid and lysine of 15:1. The pH was ad-
justed to 7.4 with 0.5 N NaOH, followed by addition of
39.6 mmol NaBCNH3 per g albumin. After incubation
for 20 hours at 40◦C under constant stirring, this solu-
tion was extensively dialyzed against distilled water and
freeze dried, equally resulting in a slightly yellow, crys-
talline powder. Content of CEL was measured by GC-MS
as described below.
Arginine-modified albumin I and II (Arg I albumin and
Arg II albumin). Respectively, 0.452 mmol glyoxal (for
Arg I albumin) or methylglyoxal (for Arg II albumin)
were added to a solution of BSA (20 mg/mL) in phos-
phate buffer (1/15 mol/L, pH 7.4). After incubation for
20 hours at 40◦C under constant stirring, the solution was
extensively dialyzed against distilled water and freeze
dried, resulting in a yellow-brown, crystalline powder.
Evaluation of the prepared AGEs by chromatographic
analysis
CML albumin and CEL albumin. CML and CEL
were measured as the corresponding trifluoroacetylated
methyl esters via GC-MS after acid hydrolysis. GC-MS
was performed on a HP 6890 Plus GC system with
HP 5973 mass selective detector, using a HP-5 phenyl-
methyl-siloxane capillary column from Agilent Tech-
nologies (Waldbronn, Germany). Protein samples were
hydrolyzed for 23 hours at 110◦C in the presence 6 N
hydrochloric acid under a nitrogen atmosphere. After
adding a suitable internal standard compound the hy-
drolysate was dried in vacuo, dissolved in 2 mL of 2 N
methanolic HCl and kept at 65◦C for 30 minutes. After
this, the solution was dried in vacuo, dissolved in 500 lL
of dichloromethane and 1 mL trifluoroacetic acid an-
hydride and kept at room temperature for 1 hour. Af-
ter drying under nitrogen, the residue was dissolved in
300 lL of dichloromethane and submitted to GC-MS
analysis. Conditions of GC and MS have been described
elsewhere [13].
Arginine derivatization. Protein samples were hy-
drolyzed for 23 hours at 110◦C in the presence 6 N
hydrochloric acid under a nitrogen atmosphere. The hy-
drolysate was dried in vacuo and dissolved in 0.2 N
sodium citrate buffer, pH 2.2. Amino acid analysis
was performed on an Alpha Plus amino acid analyzer
(LKB-Biochrom, Cambridge, UK), using a stainless steel
column (150 × 4 mm) filled with ion-exchange resin,
DC4A-spec sodium form (Benson, Reno, NV, USA).
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Composition of elution buffers, ninhydrin reagent as well
as running conditions was described elsewhere [21, 22].
Evaluation of biologic impact of AGEs
Cell line culture. HL-60 cells were obtained from
the American Type Culture Collection (Rockville, MD,
USA) and were maintained as a continuous culture
in RPMI 1640 medium supplemented with 2 mmol/L
L-glutamine, 20% heat-inactivated fetal bovine serum
(FBS) (Life Technologies, Merelbeke, Belgium) and
50 lg/mL gentamycin in a humidified atmosphere of 5%
CO2 in air at 37◦C. Medium was refreshed every 3 to
4 days. Cell cultures were free of mycoplasma.
Experimental media. HL-60 cells were cultured, over a
week period, in (1) medium alone, (2) medium containing
unmodified serum albumin (albumin was run through the
same modification process, but in the absence of the mod-
ifying compound) or AGE-modified albumin (CML albu-
min, CEL albumin, Arg I albumin, and Arg II albumin),
(3) medium containing 10 nmol/L calcitriol to differenti-
ate HL-60 toward the monocyte/macrophage phenotype
[23], and (4) a combination of (2) and (3). The conditions
(1) and (2) were included as control conditions. HL-60
has been proven to be an excellent model for studying
the differentiation of leukocytes and their capacity to de-
stroy infective agents. The monocyte/macrophage pheno-
type (after calcitriol induced differentiation) is of major
importance in the process of atherogenesis. Cell viability
at the moment of evaluation exceeded 90% as assessed
by propidium iodide exclusion by flow cytometric analy-
sis. The unmodified and modified serum albumin samples
were used at a concentration of 1 mg protein/mL, result-
ing in a final concentration of 0.136 mg CML, 0.161 mg
CEL, 0.050 mg Arg I or 0.066 mg Arg II per mL cell cul-
ture medium. AGE compounds were determined to con-
tained between 0.2 and 0.7 IU/mL endotoxin (Endosafe
Endochrome-KTM) (Charleston, SC, USA).
Evaluation methods for HL-60 cells.
Chemiluminescence production. Chemiluminescence
production by HL-60 cells was determined after 1 week
incubation in the different culture media and after read-
justment of the cell count to 1 × 106 cells/mL in every
sample. We added 500 lL of luminol solution (56 lmol/L)
and 100 lL Hanks balanced salt solution (HBSS) or
100 lL phorbol 12-myristate 13-acetate solution (PMA)
(1.5 lg/mL final concentration) to 50 lL of cell suspen-
sion. The test tube was immediately processed into a lu-
minescence analyzer (Lumicon, Hamilton, Switzerland).
The photon-counting value, which is indicated arbitrar-
ily in relative light units (RLU), was registered with
a counting interval set at 30 seconds and a total recy-
cling time of 30 minutes. Chemiluminescence production
was expressed as integrated chemiluminescence emis-
sion in counts/30 minutes, chemiluminescence peak in
counts/min and slope.
Analysis of membrane-bound CD14 expression on
HL-60 cells. Expression of CD14, a differentiation
marker and receptor for lipopolysaccharide (LPS), was
assessed by direct immunofluorescence after 3 days of cul-
ture. Fifty microliter cell suspension was incubated with
SimultestTM LeucogateTM (Becton Dickinson, San Jose,
CA, USA) at 4◦C in the dark. SimultestTM LeucogateTM
contains fluorescein isothiocyanate (FITC)-conjugated
CD45 monoclonal antibodies (anti-HLe-1) and phyco-
erythrin (PE)-conjugated CD14 monoclonal antibod-
ies (LeuTM-M3). After washing procedures, the cells
were submitted to flow cytometric analysis (FACScan)
(Becton Dickinson). Fluorescence was standardized by
microbeads (CalibriteTM particles) (Becton Dickinson)
with amplification and voltage kept constant throughout
the procedure. Analysis was performed on 10,000 events
(detector threshold forward scatter-height (FSC-H):200,
parameter FSC-H:1.00). The cell population was gated
according to forward and right-angled light scatter. Back-
ground binding was estimated by isotype-matched neg-
ative control antibodies (SimultestTM Control) (Becton
Dickinson).
BrdU-DNA synthesis. At day 7 of incubation, cell
proliferation by the measurement of the incorporation
of BrdU into the DNA was evaluated. Anti-BrdU (Bec-
ton Dickinson) was used in flow cytometric analysis to
identify cells that synthesized DNA during exposure to
BrdU (Sigma Chemical Co).
Cells were incubated for 30 minutes with BrdU
(10 lmol/L) in the CO2 incubator at 37◦C. After
two washings with 1% BSA/phosphate-buffered saline
(PBS), the pellet was resuspended in 200 lL of PBS on
ice and to fix the cells, this suspension was then slowly
added to 5 mL of 70% ethanol (−20◦C) followed by a
30-minute incubation period on ice. After centrifugation
and aspiration of the supernatant, 1 mL 2 N HCl/0.5%
Triton X-100 was slowly added to the pellet followed
by a 30-minute incubation period at room temperature
to denature the DNA. After centrifugation, 1 mL of
0.1 mol/L Na2B4O4.10 H2O, pH 8.5, was added to the pel-
let to neutralize the acid, followed by a second centrifu-
gation step. Cell concentration was adjusted with 0.5%
Tween/1.0% BSA/PBS to achieve 106 cells/test. Cells
were incubated with FITC-conjugated anti-BrdU for
30 minutes and washed once in 1 mL 0.5% Tween/1.0%
BSA/PBS, and finally resuspended in PBS containing
5 lg/mL propidium iodide before analysis by a FACScan
(Becton Dickinson).
Statistical analysis
Data are expressed as mean ± SD (N = 6). Statistical
analysis was performed using one-way repeated measures
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Fig. 1. Gas chromatography-mass spectrometry (GC-MS) chro-
matograms of native bovine serum albumin (A) compared to
the carboxymethylated (B) and carboxyethylated (C) form. N-d-
carboxymethylornithine (m/z 351), a naturally not occurring homologue
of N-e-carboxymethyllysine, was added before sample preparation and
used as an internal standard. N-e-carboxymethyllysine (m/z 392) (B)
and N-e-carboxyethyllysine (m/z 379) (C) are both products of specific
synthesis and were selectively enriched in the corresponding protein.
of analysis of variance (ANOVA) followed by a paired
Wilcoxon signed rank test in case of significant ANOVA.
A P value of less than 0.05 was considered significant.
RESULTS
Evaluation of the prepared AGEs by chromatographic
analysis
For the synthesis of albumin modified with CML and
CEL, reductive alkylation of the protein in the pres-
ence of glyoxylic acid or pyruvic acid, respectively, was
performed. This procedure offers the possibility to se-
lectively modify lysine residues avoiding other typical
Maillard reaction products as illustrated in Figure 1,
where Figure 1A shows the GC-MS chromatograms of
Table 1. Effect of advanced glycation end-product (AGE)
compounds on the characteristics of the luminol-amplified
chemiluminescence production of phorbol 12-myristate 13-acetate
(PMA)-stimulated HL-60 cells
Medium AGE Calcitriol Calcitriol + AGE
Arg I albumin
Integral 9.8 ± 6.0 13.2 ± 13.8 46.4 ± 18.8a 66.1 ± 32.6a,b
Peak 6.7 ± 3.7 5.1 ± 3.4 27.8 ± 6.6a 43.2 ± 17.9a,b
Slope 1.4 ± 1.7 0.9 ± 0.8 6.3 ± 1.9a 8.5 ± 3.8a
Arg II albumin
Integral 12.2 ± 7.5 8.1 ± 3.5 55.6 ± 37.1a 61.9 ± 38.6a
Peak 8.0 ± 3.7 6.3 ± 3.5 37.6 ± 27.4a 44.4 ± 27.8a
Slope 1.5 ± 0.8 1.7 ± 1.2 8.1 ± 5.3a 9.9 ± 9.8a
CEL albumin
Integral 8.2 ± 7.4 4.9 ± 1.8 44.1 ± 18.5a 64.7 ± 28.1a,b
Peak 4.2 ± 1.6 4.3 ± 2.4 46.5 ± 18.9a 57.4 ± 25.8a,b
Slope 2.2 ± 1.4 0.6 ± 0.7 12.9 ± 7.7a 14.4 ± 9.4a
CML albumin
Integral 2.7 ± 1.3 2.2 ± 0.6 41.9 ± 25.5a 60.9 ± 5.5a,c
Peak 2.8 ± 1.8 2.3 ± 1.4 27.0 ± 17.3a 62.3 ± 63.9a,b
Slope 0.7 ± 1.4 1.3 ± 2.4 6.8 ± 7.4a 8.7 ± 9.7a
Abbreviations are: CML, N-e-carboxymethyllysine; CEL, N-e-
carboxyethyllysine; integral (counts 103/30 min); peak (cpm 103); slope
(103); mean ± SD.
aP < 0.05 versus medium; bP < 0.05 and cP = 0.0625 versus calcitriol (N = 6).
native BSA in comparison to the carboxymethylated
(Fig. 1B) and carboxyethylated (Fig. 1C) form.
The amount of the lysine derivatives formed under
these conditions was 136 mg CML per g of protein and
161 mg CEL per g of protein, respectively, as measured
via GC-MS after acid hydrolysis. These concentrations
correspond to a lysine modification within the albumin
preparations of 74.8% (by CML) or 83.9% (by CEL). For
the albumin samples incubated with glyoxal or methylgly-
oxal, the derivatization of arginine was quantified after
acid hydrolysis on the amino acid analyzer as 67.1% for
glyoxal-modified albumin (Arg I albumin) and 83.1% for
methylglyoxal-modified albumin (Arg II albumin), re-
spectively, 50.3 and 65.7 mg/g protein. For both prepa-
rations, arginine derivatization can be explained by the
formation of imidazolinones or chemically related com-
pounds [17–19]. Compared to arginine, derivatization of
lysine in Arg I albumin and Arg II albumin was negligible.
Effect of the different AGE compounds on production
of free radicals (chemiluminescence production)
The presence of serum albumin per se in the culture
medium had no effect on the chemiluminescence produc-
tion of HL-60 cells cultured in the absence and the pres-
ence of calcitriol (data not shown). Baseline experiments,
without PMA stimulation, showed no effect of the AGE
compounds, neither in medium alone, nor in calcitriol-
supplemented medium (data not shown). The study of
the effect of AGE compounds on the PMA-stimulated
chemiluminescence production of undifferentiated
HL-60 cells, applied as control experiments, showed no
effect (Table 1). As expected, the addition of calcitriol
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Fig. 2. Representative time curves of luminol-dependent chemilumi-
nescence (CL) assay from phorbol 12-myristate 13-acetate (PMA)-
stimulated HL-60 cells cultured in medium, in medium supplemented
with Arg I albumin, Arg II albumin, N-e-carboxyethyllysine (CEL) al-
bumin, or N-e-carboxymethyllysine (CML) albumin both in the absence
and the presence of calcitriol (C). Calcitriol-treated cells are to be con-
sidered as the equivalent of monocyte/macrophage cells. In parallel to
the average results illustrated in Table 1, there is a marked increase in
response of the calcitriol-treated cells in the presence of Arg I albu-
min, CEL albumin, and CML albumin. The impact of Arg II albumin
is neutral.
Table 2. Effect of different advanced glycation end-product (AGE)
compounds on the expression of membrane bound CD14 on
calcitriol-differentiated HL-60 cells
% CD14-positive cells Mean fluorescence intensity
Calcitriol + Calcitriol +
Calcitriol AGE Calcitriol AGE
Arg I albumin 58 ± 3 62 ± 4a 768 ± 143 890 ± 150a
Arg II albumin 79 ± 3 80 ± 3 1160 ± 149 1177 ± 208
CEL albumin 71 ± 11 77 ± 9a 1695 ± 796 2075 ± 1044a
CML albumin 55 ± 9 69 ± 7a 647 ± 63 716 ± 69a
Abbreviations are: CML, N-e-carboxymethyllysine; CEL, N-e-
carboxyethyllysine. Mean ± SD.
aP < 0.05 versus calcitriol (N = 6).
to the culture medium induced cell differentiation (to-
ward the monocyte/macrophage phenotype) resulting in
a marked increase in free radical production in response
to PMA. The presence of Arg I albumin, CEL albumin,
and CML albumin in the culture medium enhanced the
PMA-stimulated chemiluminescence production of the
calcitriol differentiated HL-60 cells (Arg I albumin and
CEL albumin) (P < 0.05 versus calcitriol) and (CML al-
bumin) (P = 0.0625 versus calcitriol) (integral and peak
values) (Table 1) (Fig. 2). Even if no significant changes
were found for the slope values, the same trend was main-
tained as for the other parameters. The presence of Arg
II albumin in the calcitriol containing culture medium did
not influence the chemiluminescence production.
Effect of the different AGE compounds on the expression
of membrane-bound CD14
Undifferentiated HL-60 cells in culture do not express
CD14 on their surface membrane, CD14 expression is
induced when cells are cultured in the presence of cal-
citriol (P < 0.05). The presence of serum albumin per se
in the culture medium did not influence the CD14 expres-
sion (data not shown). Table 2 illustrates that when these
calcitriol-differentiated HL-60 cells were cultured in the
presence of Arg I albumin, CEL albumin, and CML al-
bumin the percentage of CD14-positive cells as well as
the amount of CD14 expression per cell was significantly
enhanced (P < 0.05).
Effect of the different AGE compounds on DNA
synthesis (BrdU incorporation)
The presence of serum albumin per se in the culture
medium had no effect on the DNA synthesis of HL-60
cells cultured in the absence or presence of calcitriol (data
not shown). None of the tested AGE compounds had
an effect on the undifferentiated HL-60 cells (Table 3)
(Fig. 3).
When HL-60 cells were cultured in the presence of
calcitriol resulting in a differentiation toward the mono-
cyte/macrophage phenotype, the percentage of HL-60
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Table 3. Effect of different advanced glycation end-product (AGE)
compounds on DNA synthesis [5-bromo-2′-deoxyuridine (BrdU)
incorporation] of HL-60 cells
Calcitriol +
Medium AGE Calcitriol AGE
Arg I albumin 36.5 ± 4.6 33.4 ± 6.7 27.7 ± 9.7a 34.3 ± 3.6c
Arg II albumin 36.2 ± 4.5 33.9 ± 6.9 33.0 ± 4.1b 32.0 ± 2.5
CEL albumin 30.5 ± 2.8 29.68 ± 2.0 23.3 ± 2.1a 22.1 ± 2.4
CML albumin 41.4 ± 3.2 42.1 ± 2.3 34.2 ± 3.3a 35.1 ± 0.8
Abbreviations are: CML, N-e-carboxymethyllysine; CEL, N-e-
carboxyethyllysine; BrdU incorporation (% BrdU-positive cells).
aP < 0.05; bP = 0.0625 versus medium; cP < 0.05 versus calcitriol (N = 6).
cells incorporating BrdU (synthesizing DNA) was signif-
icantly decreased (overall from 36.5 ± 4.6 to 27.7 ± 9.7%
BrdU-positive cells) (P < 0.05, N = 6), confirming the
known antiproliferative effect of calcitriol (Fig. 3). The
presence of Arg I albumin in the calcitriol-containing cul-
ture medium again induced more DNA synthesis (34.3 ±
3.6% BrdU-positive cells) (P < 0.05) (Fig. 3). No such
effect was observed for CML albumin, CEL albumin, or
Arg II albumin (Table 3).
DISCUSSION
In this study, the biologic effects of albumin containing
genuine AGE structures (CML albumin, CEL albumin,
Arg I albumin, and Arg II albumin, which are known to
be retained in uremia, were studied, with specific empha-
sis on leukocyte function. Arg I albumin, CML albumin
and CEL albumin were found to enhance free radical
production and CD14 expression of cells of the mono-
cyte/macrophage phenotype. In addition, Arg I albumin
also increased the DNA synthesis.
AGEs result from irreversible modifications of amino
acids, proteins, or peptides by carbohydrates and other
metabolites. Oxidative and carbonyl stress have been
pointed out as responsible events for their generation
in uremia [7, 24, 25]. AGEs have been reported to be
the result of inflammation [26] but at the same time they
have been shown, in vitro, to cause inflammation [27, 28].
In a recent study by Bernheim et al [27], the superoxide
production of leukocytes incubated in the presence of a
mix of AGE compounds was activated at baseline but
was attenuated upon stimulation. In this way, leukocyte
dysfunction may at baseline contribute to the inflamma-
tory status of the uremic patient while the attenuated
response upon stimulation may have its implications in
the increased susceptibility to infection.
In most in vitro studies, however, AGE-modified pro-
teins were prepared, as mixed modified samples by sim-
ple incubation of the protein or albumin solution in the
presence of glucose, generally without detailed chemical
characterization of the formed amino acid derivatives and
without the possibility to analyze individual compounds
as they are retained in uremia. In this context, it remains
a matter of debate whether the latter mixes of AGEs are
representative for the AGEs retained in vivo [29].
For the time being, it has not yet been decided which of
the individual AGE compounds defined in uremia exert
toxic biologic effects and actually virtually no individ-
ual AGEs have been shown to be bioactive [30]. In the
present study, the effect of chemically well-defined AGE
compounds, the protein-bound lysine derivatives, CML
albumin and CEL albumin, as well as the protein-bound
arginine modifications, Arg I albumin and Arg II albu-
min, induced by glyoxal and methylglyoxal, on leukocyte
functions like cell differentiation and cell proliferation,
was evaluated. To the best of our knowledge, these spe-
cific compounds, characteristic for uremic AGE reten-
tion, have not previously been submitted to an evaluation
of their separate biologic activity. Since, in the present
study, we focused each time on isolated AGE compounds
and not on heterogenously glycated AGEs (containing
several compounds together) we aimed at higher con-
centrations, to be able to link possible effects to specific
stuctures. It is of note that, in contrast to CML, up to now
no quantitative data are available for the individual argi-
nine derivatives [31]. In the past, these compounds have
been detected qualitatively using immunologic methods.
Therefore, it is not yet possible to compare the used con-
centrations with levels in uremia.
Calcitriol is known to differentiate HL-60 cells toward
the monocyte/macrophage phenotype. The latter leuko-
cyte phenotype is of major importance in the process of
atherogenesis. The separate AGE compounds, Arg I al-
bumin, CEL albumin, and CML albumin, significantly
increased the PMA-stimulated chemiluminescence pro-
duction and the CD14 expression on calcitriol differenti-
ated HL-60 cells compared to unmodified serum albumin.
An enhanced production of free radical species in the
presence of specific AGE compounds could contribute
to the inflammatory status of patients with ESRD. In ad-
dition, an overexpression of the differentiation antigen
which is a receptor for LPS could result in an overexpres-
sion of proinflammatory cytokines which may also induce
or contribute to an inflammatory status [32]. This activa-
tion could be of relevance in connection with the known
baseline inflammatory status of end-stage renal failure
patients [33]. It is of note, however, that a recent study re-
ported an inverse correlation between the concentration
of certain AGEs and the development of cardiovascular
disease in hemodialysis patients [34]. It should be con-
sidered, however, that the AGEs evaluated in the above
study might be not the ones affecting the immune or car-
diovascular system.
Our data on cell proliferation showed that only one
of the tested AGE compounds, Arg I, enhanced the
DNA synthesis of calcitriol-differentiated HL-60 cells.
An increase in cell proliferation was also reported when
Glorieux et al: Immune activating effect of specific AGE structures 1879
0
40
80
120
160
200
Co
un
ts
0
20
0
40
0
60
0
80
0
10
00
FL1-Height
36.4%
BrdU positive cell
M1
0
40
80
120
160
200
Co
un
ts
0
20
0
40
0
60
0
80
0
10
00
FL1-Height
32.9%
BrdU positive cells
M1
0
40
80
120
160
200
Co
un
ts
0
20
0
40
0
60
0
80
0
10
00
FL1-Height
27.1%
BrdU positive cells
M1
0
40
80
120
160
200
Co
un
ts
0
20
0
40
0
60
0
80
0
10
00
FL1-Height
34.1%
BrdU positive cells
M1
Fig. 3. A representative experiment of the evaluation of 5-bromo-2′-deoxyuridine (BrdU) incorporation into DNA (DNA synthesis) of HL-60
cells cultured in medium, in medium supplemented with Arg I albumin both in the absence and the presence of calcitriol [(C) and (C + Arg I
albumin)]. A marker (M1) is set on the isotype control sample to exclude aspecific staining. The percentage of BrdU-positive cells is noted.
osteoblast-like cells were cultured in the presence of
AGE, although this effect was time-dependent and cell
proliferation was found to be depressed again after a
longer (days) incubation period [35]. Glycated serum al-
bumin has also been reported to stimulate cell prolifer-
ation of vascular smooth muscle cells [36]. In contrast,
AGEs impair cell proliferation of human mesangial cells
and renal tubular cells (LLC-PK1) [37, 38]. These data
point to the fact that the effect of AGEs is, very much,
cell type dependent.
CONCLUSION
The present study points out, for the first time, that
Arg I albumin, CML albumin, and CEL albumin, which
are specific AGE compounds known to be elevated
and present in uremia, exert a biologic activity on
leukocytes from the monocyte/macrophage phenotype
which could very likely contribute to the progression of
atherosclerosis.
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